Heartflow Inc (HTFL) Investment Analysis:

1. Executive Summary:

Heartflow Inc. (HTFL) stands at the vanguard of a paradigm shift in cardiovascular diagnostics, fundamentally altering how physicians identify and manage coronary artery disease (CAD). As the leading cause of death globally, CAD imposes a staggering clinical and economic burden, projected to exceed $1 trillion in costs in the United States alone by 2035. The traditional diagnostic pathway for CAD has long been plagued by inefficiency, relying heavily on non-invasive stress tests that suffer from low diagnostic accuracy or invasive coronary angiography (ICA) which, while definitive, carries procedural risks and high costs. Heartflow addresses this critical inefficiency through its proprietary HeartFlow FFRCT Analysis, a non-invasive technology that leverages deep learning artificial intelligence (AI) and computational fluid dynamics (CFD) to model blood flow and assess arterial physiology from standard coronary CT angiography (CCTA) images.

The company recently completed a landmark initial public offering (IPO) on August 8, 2025, debuting on the Nasdaq Global Select Market under the ticker HTFL. The offering was upsized due to strong investor demand, pricing 19,166,667 shares at $19.00 per share—the top end of the range—raising approximately $364.2 million in gross proceeds. This successful capitalization event, managed by top-tier underwriters including J.P. Morgan and Morgan Stanley, has provided the company with a substantial war chest to accelerate commercial adoption, fund continued research and development, and navigate the path toward profitability.

Heartflow operates a software-as-a-service (SaaS) business model within the medical technology sector, a structure that affords it high gross margins and recurring revenue potential distinct from traditional capital-intensive medical device manufacturers. The core product, FFRCT, acts as a "gatekeeper" to the catheterization lab, allowing clinicians to distinguish between patients who require invasive intervention and those who can be safely managed with medical therapy. Clinical data from major trials such as PLATFORM and PRECISE have demonstrated that the use of HeartFlow FFRCT can reduce unnecessary invasive angiograms by over 80% while significantly lowering healthcare costs.

Beyond physiology, the company is aggressively expanding its addressable market through HeartFlow Plaque Analysis, an AI-driven tool designed to quantify and characterize coronary plaque. This strategic pivot moves the company beyond merely triaging symptomatic patients for stents (intervention) into the broader realm of preventative cardiology and long-term risk management. The recent inclusion of Plaque Analysis in reimbursement structures by the Centers for Medicare & Medicaid Services (CMS), with a dedicated payment rate of $950 established for 2025, signals a regulatory environment increasingly supportive of AI-enabled diagnostics.

Financially, Heartflow is in a phase of hyper-growth. For the third quarter of 2025, the company reported revenue of $46.3 million, representing a 41% year-over-year increase, driven by a 48% surge in case volumes. The company has issued full-year 2025 revenue guidance of $173.0 million to $173.5 million. While the company remains unprofitable with a net operating loss of $15.1 million in Q3 2025, this represents a significant improvement from prior periods, driven by gross margin expansion to 76.5% as automation efficiencies take hold.

The investment thesis for Heartflow is compelling but carries distinct risks. The company effectively created the category of FFRCT and enjoys a substantial "moat" built on intellectual property, regulatory approvals, and over a decade of clinical data. However, the competitive landscape is intensifying, most notably with the emergence of Cleerly Inc., a well-capitalized rival focusing heavily on plaque characterization. Additionally, the company’s valuation—trading at a premium multiple of sales relative to traditional medtech peers—prices in high expectations for continued execution and growth. Macroeconomic factors, such as interest rate sensitivity affecting high-duration growth stocks and the potential for healthcare spending constraints, also pose headwinds.

As Heartflow transitions from a private unicorn to a public market leader, it faces the dual challenge of scaling its commercial footprint to meet wall street expectations while defending its technological leadership against emerging AI competitors. The analysis that follows details the specific mechanics of this transition, the durability of its revenue drivers, and the realistic scenarios for shareholder returns over the next five years.

2. Business Drivers & Strategic Overview:

The strategic architecture of Heartflow Inc. is built upon resolving the "Anatomy vs. Physiology" discord that has historically complicated cardiology. To understand the business drivers, it is essential to first dissect the clinical friction the company eliminates and then analyze how its technology platform monetizes the solution.

2.1 The Clinical Imperative: Closing the Diagnostic Gap

The fundamental driver of Heartflow's business is the inefficiency of current non-invasive testing. For decades, cardiologists have relied on a binary approach to diagnosis. They either use functional tests like stress echocardiograms and nuclear perfusion scans (SPECT), or anatomical tests like standard Coronary Computed Tomography Angiography (CCTA). Both methods have significant limitations. Functional tests often fail to detect early-stage disease or accurately localize ischemia, leading to high false-positive rates. Anatomical tests (CCTA) are excellent at visualizing blockage (stenosis) but poor at determining if that blockage is actually restricting blood flow enough to cause symptoms.

Because of this uncertainty, physicians historically defaulted to the "gold standard": Invasive Coronary Angiography (ICA). This procedure involves threading a catheter through the femoral or radial artery to the heart, injecting dye, and measuring pressures with a wire (invasive FFR). While definitive, it is invasive, expensive (costing thousands of dollars), and carries risks of complications. Crucially, data indicates that more than half of patients sent to the cath lab for diagnostic ICA are found to have non-obstructive disease, meaning the procedure was clinically unnecessary.

Heartflow captures value by bridging this gap. Its technology allows for the determination of Fractional Flow Reserve (FFR)—a physiological measure of blood flow—non-invasively from the CCTA image. This means a patient can undergo a 15-minute CT scan and receive a definitive answer on both anatomy (plaque) and physiology (ischemia), negating the need for a purely diagnostic invasive angiogram. The economic value proposition is straightforward: payers and hospital systems save money by avoiding expensive cath lab procedures, and Heartflow captures a portion of that savings as high-margin software revenue.

2.2 The Technology Platform: Computational Fluid Dynamics and AI

Heartflow’s "moat" is constructed around its proprietary application of deep learning and Computational Fluid Dynamics (CFD). The process begins when a hospital uploads a standard CCTA scan to the HeartFlow cloud.

Deep Learning Anatomy Extraction: The company’s algorithms first segment the coronary anatomy, identifying the lumen boundaries and vessel, significantly faster and more accurately than human analysts. The accumulated data from hundreds of thousands of processed cases creates a data network effect; the more scans the system processes, the more robust the AI becomes at handling anatomical variations and artifacts, driving down the cost of revenue.

Physiological Simulation: Unlike competitors that may rely purely on visual machine learning assessments, HeartFlow applies the Navier-Stokes equations—complex physics equations describing fluid motion—to the 3D model. This simulates blood flow, pressure, and resistance throughout the coronary tree. The output is a color-coded 3D model providing FFR values at every point in the artery. An FFR value of ≤0.80 is the clinically validated threshold for ischemia, guiding revascularization decisions.

The Product Ecosystem: Heartflow is evolving from a single-product company into a comprehensive precision heart care platform:

1. HeartFlow FFRCT Analysis: The flagship product and current primary revenue driver. It answers the question, "Does this narrowing need a stent?".

2. HeartFlow Plaque Analysis: Recently launched and aggressively commercialized, this tool quantifies plaque volume and characterizes plaque type (calcified, non-calcified, low-attenuation). Low-attenuation plaque is a potent predictor of future myocardial infarction. This product expands the TAM to include risk stratification for asymptomatic patients and monitoring disease progression over time.

3. HeartFlow PCI Planner (Projected 2026): A pre-procedural planning tool designed for interventional cardiologists. It allows physicians to virtually "implant" stents in the software model to visualize the post-procedure physiological result before ever touching the patient. This tool is designed to enhance procedural efficiency and lock in the interventional cardiology user base.

2.3 Reimbursement and Regulatory Moat

A critical business driver for any medical technology is the reimbursement landscape. Heartflow has secured a defensible position through years of lobbying and clinical evidence generation.

Medicare Payment Leadership: For the fiscal year 2025, CMS increased the payment rate for HeartFlow FFRCT (mapped to APC 5724) to $1,017. This payment is separate and distinct from the payment for the CT scan itself (which also saw an increase to $357). Furthermore, CMS established a payment rate of $950 for AI-enabled Quantitative Plaque Analysis (APC 1151).

This dual-reimbursement structure is a powerful economic driver for hospitals. It transforms the CCTA department from a cost center into a profit center. A hospital can perform a CCTA, order both FFRCT and Plaque Analysis, and potentially receive over $2,300 in total reimbursement, while paying HeartFlow a fee that allows for a healthy facility margin. This economic alignment incentivizes hospitals to adopt the technology and utilize it frequently.

Commercial Coverage: Beyond Medicare, Heartflow has secured positive coverage decisions from major commercial payers, including UnitedHealthcare and Cigna, which began coverage for Plaque Analysis in late 2025. This expands the addressable patient population from the elderly (Medicare) to the commercially insured workforce, significantly increasing the volume of eligible scan candidates.

2.4 Clinical Evidence as a Barrier to Entry

Heartflow has erected a high barrier to entry through its relentless investment in clinical trials. The company’s technology is supported by data from over 500 peer-reviewed publications and major trials involving tens of thousands of patients.

• PLATFORM Trial: Demonstrated an 83% reduction in unnecessary invasive angiograms.

• PRECISE Trial: Validated the use of FFRCT in guiding treatment, showing outcomes equivalent to or better than standard care.

• DECIDE Registry: Recent data presented in July 2025 showed that HeartFlow Plaque Analysis altered medical management in over 50% of patients, leading to measurable reductions in LDL cholesterol—a key surrogate for reduced cardiac risk.

• FISH&CHIPS Study: A massive real-world study from the UK National Health Service (NHS) involving nearly 8,000 patients. Published in Nature Medicine, it confirmed that Total Plaque Volume (TPV) derived by HeartFlow is a powerful independent predictor of death and myocardial infarction.

This depth of evidence creates a "trust moat." While competitors like Cleerly are entering the market with strong marketing, they lack the decade-long longitudinal outcome data that HeartFlow possesses, making conservative medical guidelines stickier for the incumbent.

2.5 Market Expansion Strategy

Heartflow’s growth strategy is multipronged:

1. Deepen US Penetration: Capitalizing on the 2021 ACC/AHA Chest Pain Guidelines, which elevated CCTA to a Class 1A recommendation. The company aims to make HeartFlow Analysis the standard of care for every CCTA performed in the US.

2. International Growth: Leveraging the success in the UK, where the NHS has mandated the use of FFRCT as part of its MedTech Funding Mandate. The company is also expanding in Japan, the world’s second-largest market for CCTA, where reimbursement is established.

3. Product Upsell: Transitioning customers from ordering just FFRCT to ordering the "comprehensive analysis" (FFRCT + Plaque). The $950 plaque reimbursement is the key catalyst for this upsell strategy.

3. Financial Performance & Valuation:

Heartflow’s financial profile is characteristic of a high-growth SaaS vertical operating within healthcare: rapid top-line expansion, high and improving gross margins, and a trajectory toward narrowing operating losses. The recent IPO has provided the transparency and capital structure necessary to evaluate its standing among peers.

3.1 Recent Historical Performance (2024-2025)

The company’s performance leading up to and following its IPO demonstrates successful commercial execution.

Revenue Growth: Heartflow reported revenue of $125.8 million for the full year ended December 31, 2024, representing a 44% growth rate over the prior year. This momentum accelerated into 2025. For the third quarter ended September 30, 2025, the company reported revenue of $46.3 million, a 41% increase year-over-year compared to $32.9 million in Q3 2024.

The growth is driven by volume. Global revenue-generating cases grew 48% year-over-year in Q3 2025. The slight discrepancy between case growth (48%) and revenue growth (41%) suggests some mix shift, likely due to international pricing or volume discounts for large enterprise health system contracts, though pricing remains robust.

Gross Margin Expansion: A critical metric for Heartflow’s valuation is its gross margin, which confirms the scalability of its AI platform.

• FY 2023 Gross Margin: ~67%.

• FY 2024 Gross Margin: 75%.

• Q3 2025 Gross Margin: 76.5% (GAAP) / 76.8% (Non-GAAP).

This consistent expansion is structurally driven. As the AI algorithms improve, the "human-in-the-loop" time required to verify each analysis decreases. Automation reduces the cost of revenue (COR), allowing margins to climb toward the company’s long-term target of 80%+.

Operating Expenses and Net Loss: While growing, the company exercises discipline. Total operating expenses for Q3 2025 were $50.5 million. The net operating loss for the quarter was $15.1 million, a dramatic improvement from the $45.2 million loss in the same period of the prior year.

• Accumulated Deficit: As of March 31, 2025, the company had an accumulated deficit of $1.0 billion, reflecting the massive capital investment required over the last 15 years to develop the technology and secure regulatory clearance.

3.2 2025 Guidance and Outlook

Management has provided clear guidance for the full fiscal year 2025 following the solid Q3 performance.

• Revenue Guidance: $173.0 million to $173.5 million.

• Implied Growth: Approximately 37.5% to 38.0% year-over-year growth.

This guidance implies a strong finish to the year, with Q4 2025 revenue expected to approach $50 million. Looking further ahead, analyst consensus estimates project 2026 revenue to reach approximately $211.85 million, representing a deceleration in percentage terms to ~22%, though absolute dollar growth remains significant.

3.3 Balance Sheet and Capital Structure

The August 2025 IPO fundamentally transformed Heartflow’s balance sheet.

• Cash Position: The IPO raised approximately $364.2 million in gross proceeds. After underwriting discounts and offering expenses, net proceeds are likely in the range of $330 million.

• Debt Repayment: Part of the IPO rationale was to repay existing debt facilities.

• Runway: With a quarterly net loss narrowing to ~$15 million and a cash balance exceeding $300 million, Heartflow has a comfortable cash runway of over 5 years at the current burn rate. This provides ample time to reach the targeted cash flow breakeven point, which management aims to achieve within three years of the IPO (approx. 2028).

3.4 Valuation Multiples and Peer Comparison

As of December 3, 2025, Heartflow trades at approximately $30.00 per share.

• Market Capitalization: With approximately 85-90 million shares outstanding post-IPO, the market cap stands at roughly $2.6 billion.

• Enterprise Value (EV): Adjusting for the substantial cash balance (~$330M) and assuming minimal residual debt, the Enterprise Value is approximately $2.3 billion.

Valuation Ratios:

• Price-to-Sales (P/S) 2025E: $2.6B / $173M ≈ 15.0x.

• EV/Revenue 2025E: $2.3B / $173M ≈ 13.3x.

• EV/Revenue 2026E: $2.3B / $212M ≈ 10.8x.

Peer Context: Heartflow trades at a premium valuation compared to traditional medical device companies but aligns more closely with high-growth HealthTech and AI peers.

• Traditional MedTech (e.g., Boston Scientific, Edwards Lifesciences): Typically trade at 4x-6x forward revenue.

• High-Growth MedTech (e.g., Shockwave, Penumbra, DexCom): Historically trade at 8x-12x forward revenue during growth phases.

• AI/SaaS Healthcare (e.g., R1 RCM, Tempus): Can command 10x-15x multiples depending on growth rates.

Heartflow’s 13.3x EV/Revenue multiple indicates the market is pricing in not just medical device sales, but the higher-margin, recurring nature of its SaaS-like revenue stream. It also reflects a "scarcity premium" for being one of the few pure-play AI cardiology stocks available in the public markets.

3.5 Analyst Sentiment

The sell-side community has been supportive following the IPO. Firms including J.P. Morgan, Morgan Stanley, Piper Sandler, Stifel, and Canaccord Genuity served as underwriters and have subsequently initiated coverage with generally bullish ratings.

• Consensus Rating: Buy / Overweight.

• Price Targets: Range from $35.00 to $40.00.

• Upside Potential: The average price target of $38.60 implies approximately 28% upside from the current trading price of $30.00.

4. Risk Assessment & Macroeconomic Considerations:

While the Heartflow investment narrative is buoyed by strong technological and financial fundamentals, it is not without significant risks. Investors must weigh the company's growth prospects against competitive threats, regulatory dependencies, and broader macroeconomic headwinds.

4.1 Competitive Risks: The "Plaque vs. Flow" War

The most acute risk to Heartflow’s long-term dominance is the rise of Cleerly Inc.

• The Rival: Cleerly, a private company backed by deep-pocketed investors like Insight Partners (Series C raise of $106M), has launched a direct assault on the FFRCT philosophy.

• The Conflict: Cleerly’s marketing posits that FFR (physiology) is a late-stage marker of disease and that the true goal should be identifying plaque burden (anatomy) early to prevent heart attacks. They market their AI as "human-refined," contrasting it with Heartflow’s automated CFD approach.

• Market Impact: While Heartflow has launched its own Plaque Analysis to neutralize this differentiation, Cleerly has gained traction with some payers and providers who prefer the "prevention-first" narrative. If clinical guidelines shift decisively toward plaque-based management over ischemia-based intervention, Cleerly could capture significant market share.

• Patent Litigation: The medical device space is litigious. While no specific massive infringement suit between Cleerly and Heartflow is currently destroying value, the history of the sector (e.g., St. Jude vs. Volcano, Butterfly Network vs. Fujifilm) suggests that as competition heats up, intellectual property battles are likely. Heartflow holds extensive patents on flow simulation , while Cleerly is building an IP fortress around plaque characterization. A protracted legal battle could drain resources.

4.2 Regulatory and Reimbursement Concentration

Heartflow’s revenue model is heavily dependent on CMS.

• Rate Sensitivity: The business is currently optimized around the ~$1,000 reimbursement rate. If CMS were to re-evaluate the cost basis of AI diagnostics and cut the rate significantly (e.g., to $300) in future years, hospital margins would evaporate, severely impacting adoption. The company acknowledges this risk, noting that rate setting is an annual process subject to political and budgetary pressures.

• MAC Fragmentation: While Heartflow has secured coverage for Plaque Analysis from 5 of 7 Medicare Administrative Contractors (MACs), full national consistency is not guaranteed. Regional disparities in coverage could complicate sales efforts and limit access for certain patient populations.

4.3 Macroeconomic Factors

• Interest Rate Sensitivity: As a high-duration asset—meaning the bulk of its cash flows are expected in the distant future—Heartflow’s stock price is highly sensitive to the discount rate. If the Federal Reserve maintains higher-for-longer interest rates to combat inflation, the present value of Heartflow’s future earnings is suppressed, compressing its valuation multiple.

• Hospital Capital Cycles: Although Heartflow sells software (OpEx), it relies on hospitals having modern, high-quality CT scanners. A macroeconomic downturn that constrains hospital capital expenditure budgets could slow the upgrade cycle for scanners, thereby throttling the growth of Heartflow’s addressable market.

• Labor Shortages: The healthcare sector faces a chronic shortage of radiology technicians. Even if a hospital wants to do more CCTA scans, they are limited by the availability of staff to operate the machines. This "top-of-funnel" constraint limits the number of scans available for Heartflow to process.

4.4 IPO-Related Risks

• Lock-Up Expiration: A significant supply of shares is set to hit the market in February 2026, roughly 180 days post-IPO. Early investors, including venture capital firms and insiders, hold millions of shares with a very low cost basis. The potential for profit-taking upon lock-up expiration could create substantial selling pressure, weighing on the stock price in Q1 2026.

• Insider Activity: Post-IPO filings indicate some insider selling by executives, including CEO John Farquhar, often to cover tax obligations related to vesting equity. While standard, consistent insider selling can dampen investor sentiment. Conversely, the establishment of the 2025 Employee Stock Purchase Plan (ESPP) helps align broader employee interests with shareholders.

5. 5-Year Scenario Analysis:

Forecasting the trajectory of a disruptive technology company involves weighing the speed of adoption against potential commoditization. The following scenarios model the potential returns for Heartflow shareholders through 2030 based on different execution outcomes.

Baseline Assumptions:

• Current Price: $30.00.

• 2025 Revenue Base: $173 Million.

• Current Shares Outstanding: ~90 Million (fully diluted).

Scenario A: The Bull Case (The "Standard of Care" Victory)

• Narrative: HeartFlow FFRCT becomes the mandated standard for all stable chest pain patients in the US, UK, and Japan. The "Anatomy vs. Physiology" debate ends with HeartFlow winning both (via its integrated Plaque + FFR solution). Cleerly remains a niche player or is acquired. Reimbursement rates remain stable or increase slightly with inflation.

• Operational Metrics:

  • Revenue Growth: Averages 30% CAGR through 2030.

  • 2030 Revenue: ~$645 Million.

  • Gross Margin: Expands to 82% due to full automation.

  • Profitability: Reaches 25% EBITDA margin ($161M EBITDA).

• Valuation: The market rewards dominance with a premium multiple of 8x Sales or 35x EBITDA.

• Implied 2030 Market Cap: ~$5.2 Billion.

• Implied Share Price: ~$58.00.

• 5-Year Total Return: +93% (CAGR ~14%).

Scenario B: The Base Case (Steady but Competitive)

• Narrative: Heartflow continues to grow, but the market splits. Heartflow dominates the "symptomatic" (chest pain) market, while Cleerly captures the "preventative" (asymptomatic) market. Growth decelerates naturally as the early adopter phase ends. Reimbursement holds but does not increase.

• Operational Metrics:

  • Revenue Growth: Averages 20% CAGR.

  • 2030 Revenue: ~$430 Million.

  • Gross Margin: Stays at 78%.

  • Profitability: Reaches 12% EBITDA margin ($51M EBITDA).

• Valuation: Multiple compresses to a standard MedTech growth multiple of 5x Sales.

• Implied 2030 Market Cap: ~$2.15 Billion.

• Implied Share Price: ~$24.00.

• 5-Year Total Return: -20%.

• Investment Insight: This scenario highlights the risk of the current 15x valuation. Even with 20% annual growth, if the multiple compresses to the mean, the stock price declines.

Scenario C: The Bear Case (Commoditization & Price Compression)

• Narrative: Advancements in onsite CT scanners (GE, Siemens, Canon) allow hospitals to perform basic FFR analysis on the workstation for free or low cost, commoditizing the service. CMS cuts the reimbursement rate for off-site analysis to $400 in 2027. HeartFlow struggles to differentiate.

• Operational Metrics:

  • Revenue Growth: Slows to 8% CAGR.

  • 2030 Revenue: ~$255 Million.

  • Gross Margin: Contracts to 65% due to pricing pressure.

  • Profitability: Struggles to break even.

• Valuation: Collapses to 2x Sales.

• Implied 2030 Market Cap: ~$510 Million.

• Implied Share Price: ~$5.70.

• 5-Year Total Return: -81%.

Scenario Summary Table

This analysis suggests that the current market price of $30 is pricing in a scenario heavily weighted toward the Bull Case. The market demands flawless execution and sustained high growth to justify the current entry point.

6. Qualitative Scorecard:

The following qualitative assessment rates Heartflow across key dimensions of corporate quality on a scale of 1 to 10.

7. Conclusion & Investment Thesis:

Heartflow Inc. (HTFL) represents one of the most compelling investment opportunities in the intersection of Artificial Intelligence and Healthcare. The company has successfully industrialized a complex physiological simulation technology, secured a distinct and lucrative reimbursement code, and validated its clinical utility through incontrovertible evidence.

The Bull Thesis: The investment case is predicated on the inevitability of the non-invasive pathway. Just as exploratory surgery was replaced by advanced imaging in other specialties, diagnostic catheterization is being replaced by HeartFlow FFRCT. The company is currently the only player with a scaled, reimbursed, and comprehensive platform that addresses both physiology (FFR) and anatomy (Plaque). With a cash-rich balance sheet and a clear roadmap to profitability by 2028, Heartflow is well-positioned to compound revenue at >25% for years.

The Risks: The primary concern is valuation. At ~13x forward sales, the stock is priced for perfection. Any deceleration in growth—whether due to competitive pressure from Cleerly, macroeconomic constraints on hospital staffing, or regulatory reimbursement cuts—would lead to a swift and severe re-rating. Additionally, the approaching lock-up expiration in February 2026 presents a near-term supply overhang.

Verdict: Heartflow is a Long-Term Buy for growth-oriented investors who can tolerate volatility. The company is a category leader with a wide moat in a massive addressable market. However, disciplined investors may wish to await the volatility associated with the February 2026 lock-up expiration to build a full position, targeting an entry price closer to the $24-$26 range where the risk/reward profile is more asymmetric.

8. Technical Analysis, Price Action & Short-Term Outlook:

Price Action Context (August - December 2025): Since its IPO in August 2025 at $19.00, HTFL stock has demonstrated the volatility typical of a high-profile technology debut.

• The Rally: The stock surged from its $19 offer price to an all-time high (ATH) of $41.22. This run was fueled by the initial "AI hype," the successful upsizing of the IPO, and the initiation of bullish analyst coverage.

• The Consolidation: Since hitting that peak, the stock has corrected approximately 25%, settling into a trading range around $30.00. This pullback is healthy, allowing the initial speculative froth to cool and the shareholder base to rotate from "flippers" to long-term holders.

Moving Averages:

• 200-Day Moving Average (MA): Not Applicable. As the company has been public for less than six months, the 200-day MA does not yet exist.

• 50-Day Moving Average: The stock is currently trading slightly below its estimated 50-day moving average (approx. $32.50). This indicates that the intermediate-term trend has shifted from bullish to neutral/bearish. The stock needs to reclaim this level to re-establish an uptrend.

Support and Resistance Levels:

• Resistance: The immediate ceiling is at $33.00 (confluence of the 50-day MA and recent highs). A breakout above this level on strong volume would open the door for a retest of the analyst price target range of $35-$40.

• Support: The stock has established a firm floor in the $29.00 - $29.50 area. Below that, the 52-week low of $25.75 (post-IPO stabilization level) serves as critical support.

Short-Term Outlook (1-3 Months): The outlook for the next quarter is Neutral to Slightly Bearish.

• Catalyst Void: Following the Q3 earnings, there is a lack of immediate catalysts until the Q4 report in February.

• Lock-Up Overhang: The market is forward-looking. Traders are aware that approximately 80 million shares will become eligible for sale in February 2026. This looming supply glut often causes stocks to drift lower or underperform in the weeks leading up to the expiration date as investors front-run the potential selling.

Trading Strategy:

• Short-Term Traders: The setup favors fading rallies into the $33 resistance level, anticipating pressure ahead of the lock-up expiry.

• Long-Term Investors: The $25-$29 zone represents an attractive accumulation area. Buying near the 52-week low ($25.75) offers a favorable risk/reward ratio for holding through the volatility of 2026.